Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABT

Abbott Laboratories vs. Zimmer Biomet Holdings: Which Medical Device Stock is a Better Buy?

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 15.1%. Currently, Abbott Laboratories has a market capitalization of $211.63 billion.

Audi RS6 Avant Tactical Green With ABT Mods Borders On Perfection

Wagons are boring? Think again.

Abbott Laboratories Whale Trades For March 29

A whale with a lot of money to spend has taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 11 strange trades.

A Bearish Sign Appears On Abbott Laboratories's Chart

If history is any guide, there may be trouble ahead for shares of Abbott Laboratories (NYSE:ABT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 3.32% on an annualized basis.

5 Stocks to Buy for Stable Income in a Volatile Market

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

5 High-Quality Mega-Cap Stocks to Scoop Up Now

5 High-Quality Mega-Cap Stocks to Scoop Up Now

In addition to inflationary pressure, economic sanctions imposed on Russia by various countries and corporations in response to Russia’s invasion of Ukraine have exacerbated volatility in the global markets. As investors seek to avoid that volatility and generate stable returns, we think high-quality mega-cap stocks Pfizer (PFE), Cisco (CSCO), Abbott…

Abbott Recalls Baby Formula Manufactured At Michigan facility

Abbott Recalls Baby Formula Manufactured At Michigan facility

Abbott Laboratories (NYSE: ABT) recalls powdered baby formulas, including Similac, made at a Michigan facility after

3 Diabetes Stocks That are Better Investments Than Senseonics

3 Diabetes Stocks That are Better Investments Than Senseonics

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

What 5 Analyst Ratings Have To Say About Abbott Laboratories

What 5 Analyst Ratings Have To Say About Abbott Laboratories

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Abbott Laboratories Whale Trades For January 26

Abbott Laboratories Whale Trades For January 26

Someone with a lot of money to spend has taken a bullish stance on Abbott Laboratories (NYSE:ABT). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100's of premium titles.
One news app.

Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook

Abbott Laboratories (NYSE: ABT) has reported

Recap: Abbott Laboratories Q4 Earnings

Abbott Laboratories (NYSE:ABT) reported its Q4 earnings results on Wednesday, January 26, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

A Preview Of Abbott Laboratories's Earnings

Abbott Laboratories (NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2022-01-26. Here's what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will likely report an Earnings Per Share (EPS) of $1.20.

CNBC's Final Trades: Abbott Laboratories, Starbucks, Bank of America And This Financial Services Stock

On CNBC’s “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors named Abbott Laboratories (NYSE: ABT) as her pick.

Get all your
news in one place.

100's of premium titles.
One news app.

1 … 10 11 12 13

People

Brenda Vingiello

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Abbott Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

374,996 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play